Aradigm Inhaled Insulin Type 1 Diabetes Study Raises Efficacy Concern
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk and Aradigm may focus on type 2 diabetes only for their AERx iDMS inhaled insulin system NN1998 following disappointing glucose suppression results in a Phase III type 1 diabetes trial.